» Articles » PMID: 35821453

Differences in Aphasia Syndromes Between Progressive Supranuclear Palsy-Richardson's Syndrome, Behavioral Variant Frontotemporal Dementia and Alzheimer's Dementia

Abstract

Language impairments, hallmarks of speech/language variant progressive supranuclear palsy, also occur in Richardson's syndrome (PSP-RS). Impaired communication may interfere with daily activities. Therefore, assessment of language functions is crucial. It is uncertain whether the Aachen Aphasia Test (AAT) is practicable in PSP-RS, behavioral variant frontotemporal dementia (bvFTD) and Alzheimer's dementia (AD) and language deficits differ in these disorders. 28 PSP-RS, 24 AD, and 24 bvFTD patients were investigated using the AAT and the CERAD-Plus battery. 16-25% of all patients failed in AAT subtests for various reasons. The AAT syndrome algorithm diagnosed amnestic aphasia in 5 (23%) PSP-RS, 7 (36%) bvFTD and 6 (30%) AD patients, Broca aphasia in 1 PSP-RS and 1 bvFTD patient, Wernicke aphasia in 1 bvFTD and 3 (15%) AD patients. However, aphasic symptoms resembled non-fluent primary progressive aphasia in 14 PSP-RS patients. In up to 46% of PSP-RS patients, 61% of bvFTD and 64% of AD patients significant impairments were found in the AAT subtests spontaneous speech, written language, naming, language repetition, language comprehension and the Token subtest. The CERAD-Plus subtest semantic fluency revealed significant impairment in 81% of PSP-RS, 61% of bvFTD, 44% of AD patients, the phonemic fluency subtest in 31, 40 and 31%, respectively. In contrast to bvFTD and AD, severity of language impairment did not correlate with cognitive decline in PSP-RS. In summary, the patterns of aphasia differ between the diagnoses. Local frontal language networks might be impaired in PSP-RS, whereas in AD and bvFTD, more widespread neuropathology might underly language impairment.

Citing Articles

Pathomechanisms of neuropsychiatric disturbances in atypical parkinsonian disorders: a current view.

Jellinger K J Neural Transm (Vienna). 2025; 132(4):495-518.

PMID: 39954076 DOI: 10.1007/s00702-025-02890-7.


Pathomechanisms of cognitive impairment in progressive supranuclear palsy.

Jellinger K J Neural Transm (Vienna). 2023; 130(4):481-493.

PMID: 36862189 DOI: 10.1007/s00702-023-02613-w.

References
1.
Armstrong M, Gronseth G, Anderson D, Biller J, Cucchiara B, Dafer R . Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 80(22):2065-9. PMC: 3716407. DOI: 10.1212/WNL.0b013e318294b32d. View

2.
Blair M, Marczinski C, Davis-Faroque N, Kertesz A . A longitudinal study of language decline in Alzheimer's disease and frontotemporal dementia. J Int Neuropsychol Soc. 2007; 13(2):237-45. DOI: 10.1017/S1355617707070269. View

3.
Boeve B, Dickson D, Duffy J, Bartleson J, Trenerry M, Petersen R . Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. Eur Neurol. 2003; 49(2):72-8. DOI: 10.1159/000068502. View

4.
Burrell J, Ballard K, Halliday G, Hodges J . Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. J Alzheimers Dis. 2017; 61(2):705-715. DOI: 10.3233/JAD-170743. View

5.
Catricala E, Boschi V, Cuoco S, Galiano F, Picillo M, Gobbi E . The language profile of progressive supranuclear palsy. Cortex. 2019; 115:294-308. DOI: 10.1016/j.cortex.2019.02.013. View